Maintenance olaparib in Asian patients with germline BRCA-mutated metastatic pancreatic cancer

被引：0

作者：

Oh, Do-Youn ^{[1
]}

Park, Joon Oh ^{[2
]}

Kindler, Hedy L. ^{[3
]}

Hammel, Pascal ^{[4
]}

Reni, Michele ^{[5
]}

Van Cutsem, Eric ^{[6
]}

Macarulla, Teresa ^{[7
]}

Hall, Michael J. ^{[8
]}

Arnold, Dirk ^{[9
]}

Reinacker-Schick, Anke ^{[10
]}

Tortora, Giampaolo ^{[11
]}

Algul, Hana ^{[12
]}

O'Reilly, Eileen M. ^{[13
]}

McGuiness, David ^{[14
]}

Liu, Yu-Zhen ^{[14
]}

Cui, Karen ^{[15
]}

Schlienger, Katia ^{[16
]}

Locker, Gershon Y. ^{[15
]}

Golan, Talia ^{[17
]}

机构：

[1] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul Natl Univ Hosp, Seoul, South Korea

[2] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea

[3] Univ Chicago, Chicago, IL 60637 USA

[4] Univ Paris VII, Hop Beaujon Clichy, Paris, France

[5] IRCCS Osped San Raffaele Sci Inst, Milan, Italy

[6] Katholieke Univ Leuven, Univ Hosp Gasthuisberg, Leuven, Belgium

[7] Vall Hebron Univ Hosp, Inst Oncol, Barcelona, Spain

[8] Fox Chase Canc Ctr, Philadelphia, PA USA

[9] Asklepios Tumorzentrum Hamburg Asklepios Klin Al, Hamburg, Germany

[10] Ruhr Univ Bochum, St Josef Hosp, Bochum, Germany

[11] Fdn Policlin Gemelli IRCCS, Med Oncol Unit, Rome, Italy

[12] Tech Univ Munich, Klin Rechts Isar, Munich, Germany

[13] Memorial Sloan Kettering Canc Ctr, New York, NY USA

[14] AstraZeneca, Cambridge, England

[15] AstraZeneca, Gaithersburg, MD USA

[16] Merck & Co Inc, Kenilworth, NJ USA

[17] Tel Aviv Univ, Sheba Med Ctr, Inst Oncol, Tel Aviv, Israel

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.05.643

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MO31-6

引用

页码：S319 / S319

页数：1

共 50 条

[31] POLO: Patient-Centered Outcomes With Maintenance Olaparib in PatientsWith a Germline BRCA Mutation and Metastatic Pancreatic Cancer
Kindler, H. L.
Yoo, H.
McGuinness, D.
Cui, K. Y.
Joo, S.
Locker, G. Y.
Golan, T.
PANCREAS, 2021, 50 (07) : 1071 - 1071
[32] BUDGET IMPACT FOR OLAPARIB MAINTENANCE THERAPY FOR BRCA-MUTATED PLATINUM SENSITIVE RECURRENT OVARIAN CANCER IN PERU
Torres Toala, F. G.
Solorzano, J.
Baldi, J.
VALUE IN HEALTH, 2018, 21 : S22 - S22
[33] Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial
Senkus, Elzbieta
Delaloge, Suzette
Domchek, Susan M.
Conte, Pierfranco
Im, Seock-Ah
Xu, Binghe
Armstrong, Anne
Masuda, Norikazu
Fielding, Anitra
Robson, Mark
Tung, Nadine
INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (04) : 803 - 814
[34] Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)
Domchek, S.
Postel-Vinay, S.
Im, S-A.
Park, Y. H.
Delord, J-P.
Italiano, A.
Alexandre, J.
You, B.
Bastian, S.
Krebs, M. G.
Wang, D.
Waqar, S.
Lanasa, M.
Angell, H. K.
Lai, Z.
Gresty, C.
Opincar, L. M.
Herbolsheimer, P.
Kaufman, B.
ANNALS OF ONCOLOGY, 2019, 30 : 477 - 477
[35] EFFICACY AND SAFETY OF MAINTENANCE OLAPARIB BY PATIENT AGE IN NON-GERMLINE BRCA-MUTATED PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER IN OPINION
Skof, E.
Bjurberg, M.
Rubio Perez, M. J.
Davidson, D.
Blakeley, C.
Bennett, J.
Poveda, A.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A202 - A203
[36] BUDGET IMPACT FOR OLAPARIB MAINTENANCE THERAPY FOR BRCA-MUTATED PLATINUM SENSITIVE RECURRENT OVARIAN CANCER IN PANAMA
Torres Toala, F. G.
Solorzano, J.
Baldi, J.
Castillo-Fernandez, O.
VALUE IN HEALTH, 2018, 21 : S22 - S22
[37] SAFETY OUTCOMES OF OLAPARIB AS MAINTENANCE THERAPY FOLLOWING FIRST-LINE PLATINUM-BASED CHEMOTHERAPY FOR PATIENTS WITH BRCA-MUTATED METASTATIC PANCREATIC CANCER: RESULTS FROM THE POLO STUDY
Van Kuiken, Katelyn
Golan, Talia
Cui, Karen
Brickel, Neil
Gupta, Charu
Kindler, Hedy
ONCOLOGY NURSING FORUM, 2022, 49 (02) : E61 - E62
[38] NEW TREATMENT FOR BRCA-MUTATED METASTATIC BREAST CANCER
Aschenbrenner, Diane S.
AMERICAN JOURNAL OF NURSING, 2018, 118 (05) : 21 - 23
[39] Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer (jul, 10.1200/JCO.21.01604, 2022)
Alguel, Hana
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17) : 2112 - 2112
[40] Extended overall survival results from the POLO study of active maintenance olaparib in patients with metastatic pancreatic cancer and a germline BRCA mutation
Arnold, Dirk
Hammel, Pascal
Golan, Talia
Reni, Michele
Van Cutsem, Eric
Macarulla, Teresa
Hall, Michael J.
Park, Joon Oh
Hochhauser, Daniel
Oh, Do-Youn
Reinacher-Schick, Anke
Tortora, Giampaolo
Algul, Hana
O'reilly, Eileen M.
Sharan, Kanu
Ou, Xiaoling
Cui, Karen
Locker, Gershon Y.
Kindler, Hedy L.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 91 - 92

← 1 2 3 4 5 →